Literature DB >> 28233739

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.

Mohammad S Rezaee-Zavareh1, Khashayar Hesamizadeh2, Bita Behnava2, Seyed M Alavian2, Mohammad Gholami-Fesharaki3, Heidar Sharafi2.   

Abstract

Entities:  

Keywords:  Hepatitis C; Ledipasvir; meta-analysis; sofosbuvir; therapy

Mesh：

Substances：

Year:  2017        PMID： 28233739     DOI： 10.5604/16652681.1231562

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN： 1665-2681            Impact factor:   2.400


× No keyword cloud information.
  9 in total

1.  Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.

Authors:  Joseph K Lim; Ann Marie Liapakis; Mitchell L Shiffman; Anna S Lok; Stefan Zeuzem; Norah A Terrault; James S Park; Charles S Landis; Mohamed Hassan; Joel Gallant; Alexander Kuo; Paul J Pockros; Monika Vainorius; Lucy Akushevich; Larry Michael; Michael W Fried; David R Nelson; Ziv Ben-Ari
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-03       Impact factor: 11.382

Review 2.  Digital Marketing: A Unique Multidisciplinary Approach towards the Elimination of Viral Hepatitis.

Authors:  Mohammadreza Pourkarim; Shahnaz Nayebzadeh; Seyed Moayed Alavian; Seyyed Hassan Hataminasab
Journal:  Pathogens       Date:  2022-05-29

Review 3.  Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.

Authors:  Fardin Dolatimehr; Hamidreza Karimi-Sari; Mohammad Saeid Rezaee-Zavareh; Seyed Moayed Alavian; Bita Behnava; Mohammad Gholami-Fesharaki; Heidar Sharafi
Journal:  Daru       Date:  2017-04-20       Impact factor: 3.117

4.  Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

Authors:  Heidar Sharafi; Seyed Moayed Alavian
Journal:  World J Hepatol       Date:  2018-09-27

5.  Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.

Authors:  Ong The Due; Usa Chaikledkaew; Anne Julienne M Genuino; Abhasnee Sobhonslidsuk; Ammarin Thakkinstian
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411

6.  An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.

Authors:  Sara Majd Jabbari; Khadije Maajani; Shahin Merat; Hossein Poustchi; Sadaf G Sepanlou
Journal:  PLoS One       Date:  2021-02-10       Impact factor: 3.240

7.  Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders.

Authors:  Heidar Sharafi; Bita Behnava; Alireza Azizi-Saraji; Ali Namvar; Ali Anvar; Shima Salimi; Seyed Moayed Alavian
Journal:  Virol J       Date:  2021-10-07       Impact factor: 4.099

8.  Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.

Authors:  Daniel Melendez-Mena; Miguel Angel Mendoza-Torres; Virginia Sedeño-Monge; Víctor Hugo García Y García; Elain Rivera-García; Laura Sánchez-Reza; María Del Carmen Baxin Domínguez; Belinda Guzmán-Flores; Ygnacio Martinez-Laguna; José Manuel Coronel Espinoza; Iván Galindo-Santiago; Juan Carlos Flores-Alonso; Verónica Vallejo-Ruiz; Paulina Cortes-Hernandez; Julio Reyes-Leyva; Francisca Sosa-Jurado; Gerardo Santos-López
Journal:  PeerJ       Date:  2021-09-17       Impact factor: 2.984

9.  Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study.

Authors:  Heidar Sharafi; Seyed Hoda Alavian; Bita Behnava; Mohammad Saeid Rezaee-Zavareh; Mehri Nikbin; Seyed Moayed Alavian
Journal:  Caspian J Intern Med       Date:  2020
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.